Solid Biosciences (SLDB) Gains from Investment Securities (2018 - 2024)
Historic Gains from Investment Securities for Solid Biosciences (SLDB) over the last 7 years, with Q3 2024 value amounting to $2.9 million.
- Solid Biosciences' Gains from Investment Securities rose 1643912.78% to $2.9 million in Q3 2024 from the same period last year, while for Dec 2024 it was -$96000.0, marking a year-over-year increase of 5051.55%. This contributed to the annual value of $407000.0 for FY2024, which is 8198.85% down from last year.
- As of Q3 2024, Solid Biosciences' Gains from Investment Securities stood at $2.9 million, which was up 1643912.78% from $2.9 million recorded in Q2 2024.
- Over the past 5 years, Solid Biosciences' Gains from Investment Securities peaked at $3.1 million during Q4 2020, and registered a low of -$495000.0 during Q4 2023.
- In the last 5 years, Solid Biosciences' Gains from Investment Securities had a median value of $695596.0 in 2023 and averaged $1.2 million.
- As far as peak fluctuations go, Solid Biosciences' Gains from Investment Securities plummeted by 10593.47% in 2023, and later soared by 1643912.78% in 2024.
- Solid Biosciences' Gains from Investment Securities (Quarter) stood at $3.1 million in 2020, then plummeted by 89.77% to $319000.0 in 2021, then fell by 4.92% to $303300.0 in 2022, then tumbled by 263.2% to -$495000.0 in 2023, then skyrocketed by 694.15% to $2.9 million in 2024.
- Its last three reported values are $2.9 million in Q3 2024, $2.9 million for Q2 2024, and $417000.0 during Q1 2024.